시장보고서
상품코드
1487645

유전체학 맞춤형 의료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)

Genomics Personalized Health Market (Technology: NGS Platform, RT-PCR, Microarray, Genetic Analyzer, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 180 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

유전체학 맞춤형 의료 시장 - 조사 범위

TMR의 조사 보고서 "세계 유전체학 맞춤형 의료 시장"은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측 연도로 하여 2018년부터 2034년까지 세계 유전체학 맞춤형 의료 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 유전체학 맞춤형 의료 시장의 연평균 성장률(CAGR%)도 제시합니다.

이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서는 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하고, 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서 등을 참조하여 유전체 개인화 건강 시장을 이해했습니다, 유전체학 맞춤형 의료 시장을 이해했습니다.

시장 현황
2023년 시장 규모 91억 달러
2034년 시장 가치 330억 달러
CAGR 12.2%

이 보고서는 세계 유전체학 맞춤형 의료 시장 경쟁 구도를 심층적으로 분석합니다. 세계 유전체학 맞춤형 의료 시장에서 사업을 운영하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되었습니다. 기업 개요, 재무 상태, 최근 동향 및 SWOT는 이 보고서에서 다루는 세계 유전체학 개인화 건강 시장 기업의 속성입니다.

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약 : 시장

제4장 시장 개요

  • 서론
  • 시장 개요
  • 시장 역학
  • 시장 분석과 예측, 2020-2034년

제5장 주요 인사이트

  • 파이프라인 분석
  • 주요 제품 및 브랜드 분석
  • 주요 M&A
  • COVID-19 팬데믹의 산업에 대한 영향

제6장 세계 시장 분석과 예측 : 기술별

  • 서론과 정의
  • 주요 조사 결과/발전
  • 시장 매출 예측 : 기술별, 2020년-2034년
    • NGS 플랫폼
    • RT-PCR 플랫폼
    • 마이크로어레이
    • 유전자 분석 장비
    • 기타
  • 시장의 매력 분석 : 기술별

제7장 세계 시장 분석과 예측 : 검사 유형별

  • 서론과 정의
  • 주요 조사 결과/발전
  • 시장 매출 예측 : 검사 유형별, 2020년-2034년
    • 종양학 검사
    • 감염증 검사
    • 희귀질환 검사
    • 자가면역질환 검사
    • 산과 검사
    • 기타
  • 시장의 매력 분석 : 검사 유형별

제8장 세계 시장 분석과 예측 : 최종사용자별

  • 서론과 정의
  • 주요 조사 결과/발전
  • 시장 매출 예측 : 최종사용자별, 2020년-2034년
    • 학술기관 및 연구기관
    • 진단센터
    • 기타
  • 시장의 매력 분석 : 최종사용자별

제9장 세계 시장 분석과 예측 : 지역별

  • 주요 조사 결과
  • 시장 매출 예측 : 지역별, 2020년-2034년
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장의 매력 분석 : 지역별

제10장 북미 시장 분석과 예측

제11장 유럽 시장 분석과 예측

제12장 아시아태평양 시장 분석과 예측

제13장 라틴아메리카 시장 분석과 전망

제14장 중동 및 아프리카 시장 분석과 전망

제15장 경쟁 구도

  • 시장 경쟁 매트릭스(기업 Tier별, 기업 규모별)
  • 시장 점유율 분석 : 기업별(2023년)
  • 기업 개요
    • QIAGEN
    • Illumina, Inc.
    • Thermo Fisher Scientific, Inc.
    • Bio-Rad Laboratories, Inc.
    • Hoffmann-La Roche AG
    • Lonza Group
    • Invitae Corp
    • Genetic Technologies Limited
    • Interleukin Genetics Inc.
    • Eastern Biotech and Life Sciences
    • DNA Genotek Inc.
    • uBiome, Inc.
    • XCode Life Sciences Private Limited
LSH 24.06.10

Genomics Personalized Health Market - Scope of Report

TMR's report on the global genomics personalized health market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global genomics personalized health market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global genomics personalized health market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the genomics personalized health market.

Market Snapshot
Market Value in 2023US$ 9.1 Bn
Market Value in 2034US$ 33 Bn
CAGR12.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global genomics personalized health market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global genomics personalized health market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global genomics personalized health market.

The report delves into the competitive landscape of the global genomics personalized health market. Key players operating in the global genomics personalized health market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global genomics personalized health market profiled in this report.

Key Questions Answered in Global genomics personalized health Market Report:

  • What is the sales/revenue generated by genomics personalized health across all regions during the forecast period?
  • What are the opportunities in the global genomics personalized health market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Genomics Personalized Health Market - Research Objectives and Research Approach

The comprehensive report on the global genomics personalized health market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global genomics personalized health market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global genomics personalized health market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Genomics Personalized Health Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Genomics Personalized Health Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Genomics Personalized Health Market Analysis and Forecast, By Technology

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, By Technology, 2020-2034
    • 6.3.1. NGS Platform
    • 6.3.2. RT-PCR
    • 6.3.3. Microarray
    • 6.3.4. Genetic Analyzer
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, By Technology

7. Global Genomics Personalized Health Market Analysis and Forecast, by Test Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Test Type, 2020-2034
    • 7.3.1. Oncology Testing
    • 7.3.2. Infectious Disease Testing
    • 7.3.3. Orphan Disease Testing
    • 7.3.4. Autoimmune Disease Testing
    • 7.3.5. Obstetrics Testing
    • 7.3.6. Others
  • 7.4. Market Attractiveness Analysis, by Test Type

8. Global Genomics Personalized Health Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2020-2034
    • 8.3.1. Academics & Research Institutes
    • 8.3.2. Diagnostic Centers
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Genomics Personalized Health Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Genomics Personalized Health Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, By Technology, 2020-2034
    • 10.3.1. NGS Platform
    • 10.3.2. RT-PCR
    • 10.3.3. Microarray
    • 10.3.4. Genetic Analyzer
    • 10.3.5. Others
  • 10.4. Market Value Forecast, by Test Type, 2020-2034
    • 10.4.1. Oncology Testing
    • 10.4.2. Infectious Disease Testing
    • 10.4.3. Orphan Disease Testing
    • 10.4.4. Autoimmune Disease Testing
    • 10.4.5. Obstetrics Testing
    • 10.4.6. Others
  • 10.5. Market Value Forecast, by End-user, 2020-2034
    • 10.5.1. Academics & Research Institutes
    • 10.5.2. Diagnostic Centers
    • 10.5.3. Others
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Technology
    • 10.7.2. By Test Type
    • 10.7.3. By End-user
    • 10.7.4. By Country

11. Europe Genomics Personalized Health Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, By Technology, 2020-2034
    • 11.3.1. NGS Platform
    • 11.3.2. RT-PCR
    • 11.3.3. Microarray
    • 11.3.4. Genetic Analyzer
    • 11.3.5. Others
  • 11.4. Market Value Forecast, by Test Type, 2020-2034
    • 11.4.1. Oncology Testing
    • 11.4.2. Infectious Disease Testing
    • 11.4.3. Orphan Disease Testing
    • 11.4.4. Autoimmune Disease Testing
    • 11.4.5. Obstetrics Testing
    • 11.4.6. Others
  • 11.5. Market Value Forecast, by End-user, 2020-2034
    • 11.5.1. Academics & Research Institutes
    • 11.5.2. Diagnostic Centers
    • 11.5.3. Others
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Technology
    • 11.7.2. By Test Type
    • 11.7.3. By End-user
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Genomics Personalized Health Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, By Technology, 2020-2034
    • 12.3.1. NGS Platform
    • 12.3.2. RT-PCR
    • 12.3.3. Microarray
    • 12.3.4. Genetic Analyzer
    • 12.3.5. Others
  • 12.4. Market Value Forecast, by Test Type, 2020-2034
    • 12.4.1. Oncology Testing
    • 12.4.2. Infectious Disease Testing
    • 12.4.3. Orphan Disease Testing
    • 12.4.4. Autoimmune Disease Testing
    • 12.4.5. Obstetrics Testing
    • 12.4.6. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Technology
    • 12.6.2. By Test Type
    • 12.6.3. By End-user
    • 12.6.4. By Country/Sub-region

13. Latin America Genomics Personalized Health Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, By Technology, 2020-2034
    • 13.3.1. NGS Platform
    • 13.3.2. RT-PCR
    • 13.3.3. Microarray
    • 13.3.4. Genetic Analyzer
    • 13.3.5. Others
  • 13.4. Market Value Forecast, by Test Type, 2020-2034
    • 13.4.1. Oncology Testing
    • 13.4.2. Infectious Disease Testing
    • 13.4.3. Orphan Disease Testing
    • 13.4.4. Autoimmune Disease Testing
    • 13.4.5. Obstetrics Testing
    • 13.4.6. Others
  • 13.5. Market Value Forecast, by End-user, 2020-2034
    • 13.5.1. Academics & Research Institutes
    • 13.5.2. Diagnostic Centers
    • 13.5.3. Others
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Technology
    • 13.7.2. By Test Type
    • 13.7.3. By End-user
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Genomics Personalized Health Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, By Technology, 2020-2034
    • 14.3.1. NGS Platform
    • 14.3.2. RT-PCR
    • 14.3.3. Microarray
    • 14.3.4. Genetic Analyzer
    • 14.3.5. Others
  • 14.4. Market Value Forecast, by Test Type, 2020-2034
    • 14.4.1. Oncology Testing
    • 14.4.2. Infectious Disease Testing
    • 14.4.3. Orphan Disease Testing
    • 14.4.4. Autoimmune Disease Testing
    • 14.4.5. Obstetrics Testing
    • 14.4.6. Others
  • 14.5. Market Value Forecast, by End-user, 2020-2034
    • 14.5.1. Academics & Research Institutes
    • 14.5.2. Diagnostic Centers
    • 14.5.3. Others
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Technology
    • 14.7.2. By Test Type
    • 14.7.3. By End-user
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. QIAGEN
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Illumina, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Thermo Fisher Scientific, Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Bio-Rad Laboratories, Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Hoffmann-La Roche AG
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Lonza Group
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Invitae Corp
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Genetic Technologies Limited
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Interleukin Genetics Inc.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Eastern Biotech and Life Sciences
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. DNA Genotek Inc.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. uBiome, Inc.
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview
    • 15.3.13. XCode Life Sciences Private Limited
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Product Portfolio
      • 15.3.13.3. SWOT Analysis
      • 15.3.13.4. Financial Overview
      • 15.3.13.5. Strategic Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제